LLY vs RTX: Which Is the Better Buy?

Side-by-side comparison of Eli Lilly and Company and RTX Corporation — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-07-17.
Eli Lilly and Company · Healthcare
$1,179.09
+31.7% upside to fair value
High Conviction Grade A High Quality
VS
RTX Corporation · Industrials
$185.60
-25.2% upside to fair value
Grade D
QuantHub Verdict
LLY has more upside to fair value (+31.7%). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric LLY RTX
Current Price $1,179.09 $185.60
Fair Value Estimate $1,552.32 $138.81
Upside to Fair Value +31.7% -25.2%
Market Cap $1,110.4B $249.9B
Forward P/E 34.3x
EV / EBITDA 34.3x 18.3x
Price / Sales 14.6x 2.8x
Price / FCF 77.7x 29.9x
Revenue Growth YoY +55.5% +8.7%
Gross Margin 83.5% 20.2%
Operating Margin 45.9% 10.9%
Return on Equity 101.3% 11.2%
Dividend Yield 0.55% 0%
FCF Yield 1.29% 3.34%
Analyst Consensus Strong Buy Buy
Investment Thesis
LLY — Eli Lilly and Company
Eli Lilly is a global biopharma company whose exceptionally profitable cardiometabolic franchises, led by Mounjaro and Zepbound, are driving a high-quality growth phase: revenue rose 55.5% year over year and earnings rose 168.0% year over year in the most recent quarter, while gross, operating, and net margins were 83.5%, 45.9%, and 35.0%, respectively. Business quality is high because tirzepatid…
RTX — RTX Corporation
RTX Corporation is a leading aerospace and defense company with a strong competitive moat driven by scale and an installed base in commercial aerospace via Pratt & Whitney and Collins Aerospace, and defense through Raytheon. The company benefits from a large multi-year backlog of approximately $270 billion supporting steady cash flow and mid-single-digit organic growth. Despite solid revenue grow…
Accumulation Zones
Metric LLY RTX
Zone Low $1,164.24 $104.11
Zone High $1,319.47 $117.99
In Buy Zone? Yes No
← LLY Research    RTX Research →    All Research